Islet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetes.

Autor: Balmas E; Center for Translational Immunology, and., Chen J; Center for Translational Immunology, and., Hu AK; Center for Systems Immunology, Benaroya Research Institute, Seattle, Washington., DeBerg HA; Center for Systems Immunology, Benaroya Research Institute, Seattle, Washington., Rosasco MG; Center for Systems Immunology, Benaroya Research Institute, Seattle, Washington., Gersuk VH; Center for Systems Immunology, Benaroya Research Institute, Seattle, Washington., Serti E; Immune Tolerance Network, Bethesda, Maryland, USA., Speake C; Center for Interventional Immunology and Diabetes Clinical Research Program, Benaroya Research Institute, Seattle, Washington, USA., Greenbaum CJ; Center for Interventional Immunology and Diabetes Clinical Research Program, Benaroya Research Institute, Seattle, Washington, USA., Nepom GT; Immune Tolerance Network, Bethesda, Maryland, USA., Linsley PS; Center for Systems Immunology, Benaroya Research Institute, Seattle, Washington., Cerosaletti K; Center for Translational Immunology, and.

Publikováno v: JCI insight [JCI Insight] 2023 Nov 08; Vol. 8 (21). Date of Electronic Publication: 2023 Nov 08.

Islet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetes

Autor: Elisa Balmas, Janice Chen, Alex K. Hu, Hannah A. DeBerg, Mario G. Rosasco, Vivian H. Gersuk, Elisavet Serti, Cate Speake, Carla J. Greenbaum, Gerald T. Nepom, Peter S. Linsley, Karen Cerosaletti

Publikováno v: JCI Insight, Vol 8, Iss 21 (2023)

Variation in the preservation of β cell function in clinical trials in type 1 diabetes (T1D) has emphasized the need to define biomarkers to predict treatment response. The T1DAL trial targeted T cells with alefacept (LFA-3–Ig) and demonstrated C-

Externí odkaz: https://doaj.org/article/fc5124fb6eab4bc1a3e7082177f0b113

Psoriasis responds to intralesional injections of alefacept and may predict systemic response to intramuscular alefacept: Interim results of a single-arm, open-label study.

Autor: Gattu, Shilpa¹ (AUTHOR), Busse, Kristine² (AUTHOR), Bhutani, Tina² (AUTHOR), Chiang, Charles² (AUTHOR), Nguyen, Thao³ (AUTHOR), Becker, Emily⁴ (AUTHOR), Koo, John Y. M.² (AUTHOR) John.Koo@ucsfmedctr.org

Publikováno v: Journal of Dermatological Treatment. Apr2012, Vol. 23 Issue 2, p103-108. 6p.

Alefacept.

Autor: Frampton, James E.¹, Wagstaff, Antona J.¹

Publikováno v: American Journal of Clinical Dermatology. 2003, Vol. 4 Issue 4, p277-286. 10p. 1 Diagram, 1 Chart, 4 Graphs.

Alefacept: Its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.

Autor: Scheinfeld, Noah¹ (AUTHOR) Scheinfeld@earthlink.net

Publikováno v: Journal of Dermatological Treatment. Aug2007, Vol. 18 Issue 4, p197-208. 12p. 13 Charts.